| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2022 | GIGAMUNE, INC. | 953 INDIANA ST | SAN FRANCISCO | CA | 94107-3007 | SAN FRANCISCO | USA | R43AI170407 | Engineered TCR-Treg Cell Therapies Targeting Type 1 Diabetes Autoantigens | 000 | 1 | NIH | 4/9/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $300,000 ) |
| | 2024 | 2024 | GIGAMUNE, INC. | 953 INDIANA ST | SAN FRANCISCO | CA | 94107-3007 | SAN FRANCISCO | USA | R43HL174204 | In vivo Sickle Cell Disease Gene Therapy Using a Novel Virus Like Particle | 000 | 1 | NIH | 9/5/2024 | $300,000 |
| | 2024 | 2021 | GIGAMUNE, INC. | 953 INDIANA ST | SAN FRANCISCO | CA | 94107-3007 | SAN FRANCISCO | USA | R43CA265475 | Engineered TCR-T Cell Therapies Targeting Shared Tumor Associated Antigens | 000 | 1 | NIH | 3/4/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $650,294 ) |
| | 2023 | 2023 | GIGAMUNE, INC. | 953 INDIANA ST | SAN FRANCISCO | CA | 94107-3007 | SAN FRANCISCO | USA | R43AR082726 | Delivery of Full Length Dystrophin to Muscle Cells for DMD Gene Therapy | 000 | 1 | NIH | 8/22/2023 | $295,294 |
| | 2023 | 2023 | GIGAMUNE, INC. | 953 INDIANA STREET | SAN FRANCISCO | CA | 94107 | SAN FRANCISCO | USA | R43AI179244 | In vivo Gene Delivery to Regulatory T Cells to Drastically Reduce the Cost of Regulatory T Cell Therapy | 000 | 1 | NIH | 4/19/2023 | $300,000 |
| | 2023 | 2023 | GIGAMUNE, INC. | 953 INDIANA STREET | SAN FRANCISCO | CA | 94107 | SAN FRANCISCO | USA | R43AI170407 | Engineered TCR-Treg Cell Therapies Targeting Type 1 Diabetes Autoantigens | 000 | 1 | NIH | 5/3/2023 | $55,000 |
| | 2023 | 2021 | GIGAMUNE, INC. | 953 INDIANA ST | SAN FRANCISCO | CA | 94107-3007 | SAN FRANCISCO | USA | R43CA257260 | Engineered TCR-T Cell Therapy Targeting Driver Mutations in NSCLC | 000 | 1 | NIH | 10/18/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $300,000 ) |
| | 2022 | 2022 | GIGAMUNE, INC. | 953 INDIANA STREET | SAN FRANCISCO | CA | 94107 | SAN FRANCISCO | USA | R43AI170407 | Engineered TCR-Treg Cell Therapies Targeting Type 1 Diabetes Autoantigens | 000 | 1 | NIH | 8/11/2022 | $300,000 |
|
| Issue Date FY: 2021 ( Subtotal = $800,000 ) |
| | 2021 | 2021 | GIGAMUNE, INC. | 1 TOWER PL STE 750 | SOUTH SAN FRANCISCO | CA | 94080-1800 | SAN MATEO | USA | R43CA257260 | Engineered TCR-T Cell Therapy Targeting Driver Mutations in NSCLC | 000 | 1 | NIH | 4/28/2021 | $400,000 |
| | 2021 | 2021 | GIGAMUNE, INC. | 1 TOWER PL STE 750 | SOUTH SAN FRANCISCO | CA | 94080-1800 | SAN MATEO | USA | R43CA265475 | Engineered TCR-T Cell Therapies Targeting Shared Tumor Associated Antigens | 000 | 1 | NIH | 7/22/2021 | $400,000 |
| | 2021 | 2018 | GIGAMUNE, INC. | 1 TOWER PL STE 750 | SOUTH SAN FRANCISCO | CA | 94080-1800 | SAN MATEO | USA | R43CA232942 | Recombinant TIL Cell Therapy for Salvage Solid Tumor Patients | 000 | 1 | NIH | 1/25/2021 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $300,000 ) |
| | 2018 | 2018 | GIGAMUNE, INC. | 1 TOWER PL STE 750 | SOUTH SAN FRANCISCO | CA | 94080-1832 | SAN MATEO | USA | R43CA232942 | Recombinant TIL Cell Therapy for Salvage Solid Tumor Patients | 000 | 1 | NIH | 9/5/2018 | $300,000 |
|
|
